Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DTYMK | P23919 | 1/20 | 0.48 |
| ▸ | HCAR3 | P49019 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | CASP6 | P55212 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
| ▸ | RXRA | P19793 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL297962 | 0.86 | SIRT6 (0.49) | ALDH1A1TSHRKDM4EHTTSMN1; SMN2 | |
| SCHEMBL28127763 | 0.83 | DTYMK (0.45) | DTYMKHCAR3ALDH1A1TSHRKDM4E | |
| SCHEMBL15895080 | 0.78 | DTYMK (0.57) | DTYMKHCAR3ALDH1A1TSHRCASP6 | |
| SCHEMBL10653362 | 0.78 | DTYMK (0.57) | DTYMKALDH1A1TSHRCASP6CYP19A1 | |
| SCHEMBL297623 | 0.77 | ALDH1A1 (0.58) | ALDH1A1TSHRKDM4EGLACASP6 | |
| SCHEMBL6390864 | 0.76 | DTYMK (0.58) | DTYMKALDH1A1TSHRCASP6CYP19A1 | |
| SCHEMBL7497984 | 0.76 | DTYMK (0.51) | DTYMKHCAR3ALDH1A1TSHRKDM4E | |
| SCHEMBL12125635 | 0.76 | PDGFRB (0.47) | ALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL12125717 | 0.76 | DTYMK (0.43) | DTYMKHCAR3ALDH1A1TSHRKDM4E | |
| SCHEMBL295501 | 0.76 | DTYMK (0.43) | DTYMKHCAR3ALDH1A1TSHRKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109053723-B | Sulfonamide derivatives and pharmaceutical use thereof | EA制药株式会社 | 2021-09-03 | — | — | CN | disclosed |
| EP-3064491-B1 | SULFONAMIDE DERIVATIVE AND MEDICINAL USE THEREOF | EA PHARMA CO LTD (JP) | 2020-01-08 | — | — | EP | disclosed |
| US-9822110-B2 | Sulfonamide derivative and pharmaceutical use thereof | EA PHARMA CO., LTD. (JP) | 2017-11-21 | — | — | US | disclosed |
| US-9822110-B2 | Sulfonamide derivative and pharmaceutical use thereof | EA PHARMA CO., LTD. (JP) | 2017-11-21 | — | — | US | disclosed |
| US-9822110-B2 | Sulfonamide derivative and pharmaceutical use thereof | EA PHARMA CO., LTD. (JP) | 2017-11-21 | — | — | US | disclosed |
| EP-3064491-A1 | SULFONAMIDE DERIVATIVE AND MEDICINAL USE THEREOF | EA Pharma Co., Ltd. (JP) | 2016-09-07 | — | — | EP | disclosed |
| US-20160244451-A1 | SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | AJINOMOTO CO., INC. (JP) | 2016-08-25 | — | — | US | disclosed |
| US-20160244451-A1 | SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | AJINOMOTO CO., INC. (JP) | 2016-08-25 | — | — | US | disclosed |
| US-20160244451-A1 | SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | AJINOMOTO CO., INC. (JP) | 2016-08-25 | — | — | US | disclosed |
| US-8546610-B2 | Method for preparing phenylalanine derivatives having quinazoline-dione skeleton and intermediates for use in the preparation of the derivatives | AJINOMOTO CO., INC. (JP) | 2013-10-01 | — | — | US | disclosed |
| US-20110313154-A1 | METHOD FOR PREPARING PHENYLALANINE DERIVATIVES HAVING QUINAZOLINE-DIONE SKELETON AND INTERMEDIATES FOR USE IN THE PREPARATION OF THE DERIVATIVES | AJINOMOTO CO., INC. (JP) | 2011-12-22 | — | — | US | disclosed |
| US-20110313154-A1 | METHOD FOR PREPARING PHENYLALANINE DERIVATIVES HAVING QUINAZOLINE-DIONE SKELETON AND INTERMEDIATES FOR USE IN THE PREPARATION OF THE DERIVATIVES | AJINOMOTO CO., INC. (JP) | 2011-12-22 | — | — | US | disclosed |
| US-20110313154-A1 | METHOD FOR PREPARING PHENYLALANINE DERIVATIVES HAVING QUINAZOLINE-DIONE SKELETON AND INTERMEDIATES FOR USE IN THE PREPARATION OF THE DERIVATIVES | AJINOMOTO CO., INC. (JP) | 2011-12-22 | — | — | US | disclosed |
| US-8058432-B2 | Method for preparing phenylalanine derivatives having quinazoline-dione skeleton and intermediates for use in the preparation of derivatives | AJINOMOTO CO., INC. (JP) | 2011-11-15 | — | — | US | disclosed |
| US-8058432-B2 | Method for preparing phenylalanine derivatives having quinazoline-dione skeleton and intermediates for use in the preparation of derivatives | AJINOMOTO CO., INC. (JP) | 2011-11-15 | — | — | US | disclosed |
| US-8058432-B2 | Method for preparing phenylalanine derivatives having quinazoline-dione skeleton and intermediates for use in the preparation of derivatives | AJINOMOTO CO., INC. (JP) | 2011-11-15 | — | — | US | disclosed |
| US-20090318688-A1 | METHOD FOR PREPARING PHENYLALANINE DERIVATIVES HAVING QUINAZOLINE-DIONE SKELETON AND INTERMEDIATES FOR USE IN THE PREPARATION OF DERIVATIVES | AJINOMOTO CO., INC. (JP) | 2009-12-24 | — | — | US | disclosed |
| US-20090318688-A1 | METHOD FOR PREPARING PHENYLALANINE DERIVATIVES HAVING QUINAZOLINE-DIONE SKELETON AND INTERMEDIATES FOR USE IN THE PREPARATION OF DERIVATIVES | AJINOMOTO CO., INC. (JP) | 2009-12-24 | — | — | US | disclosed |
| US-20090318688-A1 | METHOD FOR PREPARING PHENYLALANINE DERIVATIVES HAVING QUINAZOLINE-DIONE SKELETON AND INTERMEDIATES FOR USE IN THE PREPARATION OF DERIVATIVES | AJINOMOTO CO., INC. (JP) | 2009-12-24 | — | — | US | disclosed |
| EP-2103601-A1 | PROCESS FOR PRODUCTION OF PHENYLALANINE DERIVATIVES HAVING QUINAZOLINEDIONE SKELETONS AND INTERMEDIATES FOR THE PRODUCTION | Ajinomoto Co., Inc. (JP) | 2009-09-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160244451-A1 | SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | ITGA1, ITGB7, ITGB4 | DTYMK 4100/4885HCAR3 2269/4885ALDH1A1 273/4885 |
| US-20090318688-A1 | METHOD FOR PREPARING PHENYLALANINE DERIVATIVES HAVING QUINAZOLINE-DIONE SKELETON AND INTERMEDIATES FOR USE IN THE PREPARATION OF DERIVATIVES | PAH, DDC, AADAT | DTYMK 1464/4885HCAR3 1295/4885ALDH1A1 985/4885 |
| US-20110313154-A1 | METHOD FOR PREPARING PHENYLALANINE DERIVATIVES HAVING QUINAZOLINE-DIONE SKELETON AND INTERMEDIATES FOR USE IN THE PREPARATION OF THE DERIVATIVES | PAH, DDC, ASNS | DTYMK 1551/4885HCAR3 1244/4885ALDH1A1 1454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.